<p>MannKind（納斯達克：MNKD - 獲取免費報告）於週三發佈了季度財報。這家生物製藥公司報告本季度每股收益為 0.03 美元，符合分析師的共識預期 0.03 美元，Zacks 報道。MannKind 的淨利潤率為 8.07%，股本回報率為負 17.74%。該公司本季度的收入為 7678 萬美元，而分析師的預期為 7499 萬美元。</p>
<h2>MannKind 價格表現</h2>
<p>週四交易時段，納斯達克 MNKD 下跌 0.20 美元，報 5.28 美元。該公司股票成交量為 2,371,934 股，較其平均成交量 1,924,207 股有所增加。該公司的市值為 14.5 億美元，市盈率為 75.37，貝塔值為 1.28。MannKind 的 52 周低點為 3.86 美元，52 周高點為 7.63 美元。該公司的 50 日移動平均線為 6.04 美元，200 日移動平均線為 6.28 美元。</p>
<h2>華爾街分析師觀點</h2>
<p>幾位分析師最近對該股票進行了評論。富國銀行於 12 月 20 日星期五發布的研究報告中對 MannKind 的股票進行了覆蓋，給予 “增持” 評級，並設定 9.00 美元的目標價。StockNews.com 在週三的研究報告中將 MannKind 的評級從 “持有” 上調至 “買入”。Wedbush 在週四的報告中重申了 “跑贏大盤” 的評級，並對 MannKind 的股票設定了 11.00 美元的目標價。最後，加拿大皇家銀行在 12 月 19 日的研究報告中將 MannKind 的股票評級從 “行業表現” 上調至 “跑贏大盤”，並將其目標價從 7.00 美元上調至 10.00 美元。八位分析師對該股票給予了買入評級，一位分析師給予了強烈買入評級。根據 MarketBeat 的數據，該股票的平均評級為 “買入”，平均目標價為 9.21 美元。</p>
<p><strong>查看我們關於 MannKind 的最新報告</strong></p>
<h2>關於 MannKind</h2>
<p>（獲取免費報告）</p>
<p>MannKind Corporation 是一家生物製藥公司，專注於開發和商業化用於內分泌和孤兒肺病的吸入治療產品。它提供 Afrezza，一種用於改善糖尿病成人血糖控制的吸入胰島素，以及 V-Go 可穿戴胰島素輸送設備，提供成人持續的皮下胰島素輸注。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票超過 MannKind</li>
<li>關於 Markup 計算器</li>
<li>波動性迴歸：3 只股票緩解標準普爾 500 的波動</li>
<li>如何找到值得投資和交易的便士股票</li>
<li>2 個催化劑可能推動 NVIDIA 股票在今年上漲 30%</li>
<li>為什麼這些公司被認為是藍籌股？</li>
<li>通用汽車的股票回購是否使股票對投資者可買？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA"/></p>
<h2>你現在應該投資 1000 美元在 MannKind 嗎？</h2>
<p>在你考慮 MannKind 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 MannKind 並不在名單上。</p>
<p>雖然 MannKind 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

曼恩凱德生物醫療

<p>曼恩凱德生物醫療（NASDAQ:MNKD）公佈了季度財報，每股收益為 0.03 美元，符合分析師的預期。該公司的淨利潤率為 8.07%，股本回報率為負 17.74%。本季度收入為 7678 萬美元，超過了 7499 萬美元的預測。分析師對曼恩凱德給予了 “買入” 評級，目標價格範圍在 9.00 美元到 11.00 美元之間。該股票交易下跌至 5.28 美元，市值為 14.5 億美元，市盈率為 75.37</p>

<p>MannKind (NASDAQ:MNKD - Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.03 EPS for the quarter, hitting analysts' consensus estimates of $0.03, Zacks reports. MannKind had a net margin of 8.07% and a negative return on equity of 17.74%. The business had revenue of $76.78 million for the quarter, compared to analysts' expectations of $74.99 million.</p>
<div class="lb-trans"><p>MannKind（納斯達克：MNKD - 獲取免費報告）於週三發佈了季度財報。這家生物製藥公司報告本季度每股收益為 0.03 美元，符合分析師的共識預期 0.03 美元，Zacks 報道。MannKind 的淨利潤率為 8.07%，股本回報率為負 17.74%。該公司本季度的收入為 7678 萬美元，而分析師的預期為 7499 萬美元。</p>
</div><h2>MannKind Price Performance</h2>
<div class="lb-trans"><h2>MannKind 價格表現</h2>
</div><p>NASDAQ MNKD traded down $0.20 during trading hours on Thursday, hitting $5.28. 2,371,934 shares of the company's stock traded hands, compared to its average volume of 1,924,207. The company has a market capitalization of $1.45 billion, a PE ratio of 75.37 and a beta of 1.28. MannKind has a 52-week low of $3.86 and a 52-week high of $7.63. The firm's 50-day moving average is $6.04 and its 200-day moving average is $6.28.</p>
<div class="lb-trans"><p>週四交易時段，納斯達克 MNKD 下跌 0.20 美元，報 5.28 美元。該公司股票成交量為 2,371,934 股，較其平均成交量 1,924,207 股有所增加。該公司的市值為 14.5 億美元，市盈率為 75.37，貝塔值為 1.28。MannKind 的 52 周低點為 3.86 美元，52 周高點為 7.63 美元。該公司的 50 日移動平均線為 6.04 美元，200 日移動平均線為 6.28 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Several analysts recently commented on the stock. Wells Fargo &amp; Company initiated coverage on shares of MannKind in a research report on Friday, December 20th. They set an &#34;overweight&#34; rating and a $9.00 price target on the stock. StockNews.com upgraded MannKind from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Wednesday. Wedbush reissued an &#34;outperform&#34; rating and issued a $11.00 price target on shares of MannKind in a report on Thursday. Finally, Royal Bank of Canada upgraded shares of MannKind from a &#34;sector perform&#34; rating to an &#34;outperform&#34; rating and upped their price target for the stock from $7.00 to $10.00 in a research report on Thursday, December 19th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of &#34;Buy&#34; and an average price target of $9.21.</p>
<div class="lb-trans"><p>幾位分析師最近對該股票進行了評論。富國銀行於 12 月 20 日星期五發布的研究報告中對 MannKind 的股票進行了覆蓋，給予 “增持” 評級，並設定 9.00 美元的目標價。StockNews.com 在週三的研究報告中將 MannKind 的評級從 “持有” 上調至 “買入”。Wedbush 在週四的報告中重申了 “跑贏大盤” 的評級，並對 MannKind 的股票設定了 11.00 美元的目標價。最後，加拿大皇家銀行在 12 月 19 日的研究報告中將 MannKind 的股票評級從 “行業表現” 上調至 “跑贏大盤”，並將其目標價從 7.00 美元上調至 10.00 美元。八位分析師對該股票給予了買入評級，一位分析師給予了強烈買入評級。根據 MarketBeat 的數據，該股票的平均評級為 “買入”，平均目標價為 9.21 美元。</p>
</div><p><strong>Check Out Our Latest Report on MannKind</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 MannKind 的最新報告</strong></p>
</div><h2>About MannKind</h2>
<div class="lb-trans"><h2>關於 MannKind</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.</p>
<div class="lb-trans"><p>MannKind Corporation 是一家生物製藥公司，專注於開發和商業化用於內分泌和孤兒肺病的吸入治療產品。它提供 Afrezza，一種用於改善糖尿病成人血糖控制的吸入胰島素，以及 V-Go 可穿戴胰島素輸送設備，提供成人持續的皮下胰島素輸注。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than MannKind</li>
<li>About the Markup Calculator</li>
<li>Volatility Is Back: 3 Stocks To Cushion the S&amp;P 500's Swings</li>
<li>How to find penny stocks to invest and trade</li>
<li>2 Catalysts That Could Push NVIDIA Stock Up 30% This Year</li>
<li>Why Are These Companies Considered Blue Chips?</li>
<li>Do GM Stock Buybacks Make the Stock Buyable For Investors?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 MannKind</li>
<li>關於 Markup 計算器</li>
<li>波動性迴歸：3 只股票緩解標準普爾 500 的波動</li>
<li>如何找到值得投資和交易的便士股票</li>
<li>2 個催化劑可能推動 NVIDIA 股票在今年上漲 30%</li>
<li>為什麼這些公司被認為是藍籌股？</li>
<li>通用汽車的股票回購是否使股票對投資者可買？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=MNKD"/></p>
<h2>Should You Invest $1,000 in MannKind Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 MannKind 嗎？</h2>
</div><p>Before you consider MannKind, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 MannKind 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 MannKind 並不在名單上。</p>
</div><p>While MannKind currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MannKind 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

曼恩凱德生物醫療（NASDAQ:MNKD）公佈財報結果